Evogene Ltd. (NASDAQ:EVGN) Short Interest Update

Evogene Ltd. (NASDAQ:EVGN) was the recipient of a significant decline in short interest in the month of April. As of April 15th, there was short interest totaling 169,681 shares, a decline of 29.1% from the March 31st total of 239,261 shares. Currently, 2.1% of the company’s shares are short sold. Based on an average daily volume of 54,207 shares, the short-interest ratio is currently 3.1 days.

Hedge Funds Weigh In On Evogene

Large investors have recently bought and sold shares of the business. XTX Topco Ltd bought a new position in Evogene in the fourth quarter worth approximately $25,000. Jane Street Group LLC raised its stake in Evogene by 58.0% in the first quarter. Jane Street Group LLC now owns 33,732 shares of the biotechnology company’s stock worth $42,000 after buying an additional 12,387 shares in the last quarter. Finally, Citadel Advisors LLC raised its stake in Evogene by 169.4% in the third quarter. Citadel Advisors LLC now owns 57,575 shares of the biotechnology company’s stock worth $66,000 after buying an additional 36,206 shares in the last quarter. Institutional investors own 10.40% of the company’s stock.

Evogene Trading Up 2.9%

Shares of NASDAQ EVGN traded up $0.02 during trading hours on Thursday, reaching $0.78. The stock had a trading volume of 46,288 shares, compared to its average volume of 50,256. The firm has a market cap of $6.80 million, a price-to-earnings ratio of -0.67 and a beta of 1.39. The business’s fifty day moving average price is $0.81 and its two-hundred day moving average price is $1.01. Evogene has a 52-week low of $0.72 and a 52-week high of $2.42.

Evogene (NASDAQ:EVGN) last issued its quarterly earnings data on Saturday, February 14th. The biotechnology company reported ($0.61) EPS for the quarter. The business had revenue of $0.31 million during the quarter. Evogene had a negative return on equity of 121.44% and a negative net margin of 214.57%.

Evogene Company Profile

Evogene Ltd. is a biotechnology company specializing in the use of computational and predictive biology technologies to design and develop novel products for agriculture and human health. Founded in 2002 and headquartered in Rehovot, Israel, the company has built a proprietary computational platform that integrates genomics, machine learning and data analytics to identify gene targets and biological traits. Evogene’s platform serves as the backbone for its research and development efforts, enabling the discovery of enhanced crop traits, microbial solutions and microbiome-based diagnostics and therapeutics.

In the agricultural sector, Evogene applies its platform to improve crop performance across a range of parameters, including yield enhancement, stress tolerance and resistance to pests and pathogens.